HIV-1 Infection - Pipeline Review, H2 2011

HIV-1 Infection - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'HIV-1 Infection - Pipeline Review, H2 2011', provides an overview of the HIV-1 Infection therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. 'HIV-1 Infection - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV-1 Infection.
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of HIV-1 Infection therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV-1 Infection Overview
Therapeutics Development
An Overview of Pipeline Products for HIV-1 Infection
HIV-1 Infection Therapeutics under Development by Companies
HIV-1 Infection Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
HIV-1 Infection Therapeutics - Products under Development by Companies
HIV-1 Infection Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in HIV-1 Infection Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
GlaxoSmithKline plc
Merck & Co., Inc.
United Biomedical, Inc.
Biotron Limited
Aphios Corporation
Japan Tobacco Inc.
Koronis Pharmaceuticals, Inc.
Ardea Biosciences, Inc.
ConjuChem Biotechnologies Inc.
Critical Outcome Technologies Inc.
Nutri Pharma ASA
Vironova AB
Argos Therapeutics, Inc.
Cytheris SA
Heat Biologics, Inc.
Etubics Corporation
Tobira Therapeutics, Inc.
Tibotec Pharmaceuticals Ltd.
Kemin Industries, Inc.
ViiV Healthcare
RFS Pharma, LLC
HIV-1 Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Elvitegravir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Edurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isentress + Kaletra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zovirax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Efavirenz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Zidovudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darunavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viramune + Truvada - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Telzir + Norvir + Abacavir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tenofovir + Abacavir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Lamivudine + Stavudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Efavirenz + Lamivudine + Stavudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Lamivudine + Tenofovir Disoproxil Fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Invirase + Emtricitabine + Tenofavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
572-Trii - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hepavax-Gene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIV-1 Infection Therapeutics – Drug Profile Updates
HIV-1 Infection Therapeutics - Discontinued Products
HIV-1 Infection - Featured News
Sep 19, 2011: Gilead's Second Pivotal Phase III Clinical Study Of Quad Regimen Meets 48-Week Primary Objective
Aug 15, 2011: Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective In Pivotal Phase III Clinical Study 102
Aug 10, 2011: Gilead Sciences Receives FDA Approval For Complera For HIV-1 Infection In Treatment-Naïve Adults
Jul 20, 2011: Gilead Announces Encouraging Phase III Clinical Trial Results Of Elvitegravir
Jul 19, 2011: Janssen Presents Phase III Safety And Efficacy Data Of EDURANT In HIV At International AIDS Society Conference
Jul 18, 2011: Merck's ISENTRESS In Combination Therapy Demonstrated Efficacy In Phase II Study Extending To Nearly Five Years In Previously Untreated Adults With HIV-1
Jul 18, 2011: Bionor Pharma Presents Data From Phase IIb Study Of Vacc-4x At IAS Conference
May 20, 2011: FDA Approves EDURANT (rilpivirine) For Use in Treatment-Naïve Adults with HIV-1
Mar 23, 2011: Gilead's Phase III Clinical Trial Of Elvitegravir Meets 48-Week Primary Objective
Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for HIV-1 Infection, H2 2011
Products under Development for HIV-1 Infection – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Abbott Laboratories, H2 2011
GlaxoSmithKline plc, H2 2011
Merck & Co., Inc., H2 2011
United Biomedical, Inc., H2 2011
Biotron Limited, H2 2011
Aphios Corporation, H2 2011
Japan Tobacco Inc., H2 2011
Koronis Pharmaceuticals, Inc., H2 2011
Ardea Biosciences, Inc., H2 2011
ConjuChem Biotechnologies Inc., H2 2011
Critical Outcome Technologies Inc., H2 2011
Nutri Pharma ASA, H2 2011
Vironova AB, H2 2011
Argos Therapeutics, Inc., H2 2011
Cytheris SA, H2 2011
Heat Biologics, Inc., H2 2011
Etubics Corporation, H2 2011
Tobira Therapeutics, Inc., H2 2011
Tibotec Pharmaceuticals Ltd., H2 2011
Kemin Industries, Inc., H2 2011
ViiV Healthcare, H2 2011
RFS Pharma, LLC, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
HIV-1 Infection Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for HIV-1 Infection, H2 2011
Products under Development for HIV-1 Infection – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011